STOCK TITAN

NYMX - $NYMX STOCK NEWS

Welcome to our dedicated page for NYMX news (Ticker: $NYMX), a resource for investors and traders seeking the latest updates and insights on NYMX stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NYMX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NYMX's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.81%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.89%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.53%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-63.85%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.95%
Tags
NYMX

Nasdaq:NYMX

NYMX Rankings

NYMX Stock Data

18.25M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About NYMX

nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.